Extracorporeal Membrane Oxygenation for Calcium Channel Blocker Intoxication: A Multicenter Retrospective Registry
April Slamowitz1, Todd Sweberg1, Katie Labgold2,3
1From the Department of Pediatric Critical Care, Cohen Children's Medical Center, Northwell Health, New Hyde Park, New York.
Abstract:
Calcium channel blocker (CCB) toxicity can lead to cardiogenic shock and circulatory collapse. Extracorporeal membrane oxygenation (ECMO) has been used as salvage therapy when conventional treatments fail, but outcomes data-especially comparing pediatric and adult populations-are limited. We conducted a retrospective analysis of the Extracorporeal Life Support Organization (ELSO) registry from 2015 to 2023, identifying 157 patients aged greater than or equal to 28 days with CCB toxicity. The primary outcome was survival to discharge. Univariate logistic regression identified survival-associated factors. Overall survival was higher in pediatric patients, compared to adults (80% vs . 63%, p = 0.0536). Veno-arterial ECMO was used in 90% of cases. Extracorporeal membrane oxygenation use increased over time without a decrease in survival. Higher age (1 year increase: odds ratio [OR] = 0.97/year, 95% confidence interval [CI]: 0.95-0.99) and lower arterial pH (per 0.1 pH increase, OR = 1.39, 95% CI: 1.04-1.86) had lower unadjusted odds of survival. The presence of pre-ECMO cardiac arrest (OR = 0.29, 95% CI: 0.12-0.65) and use of extracorporeal cardiopulmonary resuscitation (CPR) (OR = 8.27, 95% CI: 1.91-57) had lower unadjusted odds of survival. Extracorporeal membrane oxygenation is increasingly used as a rescue therapy for severe CCB toxicity. Factors such as younger age, preserved pH, and absence of cardiac arrest before cannulation are associated with improved outcomes.
More Related Videos
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
Related Concept Videos
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome IV: Interprofessional Care
Antihypertensive Drugs: Action of Calcium Channel Blockers
